ADIPOQ and Alzheimer disease: Hence, adipokines and their receptors, particularly adiponectin and its mimetic peptides via AdipoR1 activation, represent an emerging, novel and attractive potential therapeutic target for the prevention of AD and other neuropathological disorders [14–16, 21, 35–37, 69–73].